Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure - Takeaways - MDSpire

Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure

  • By

  • Fang Zeng

  • Fei Tan

  • Dehui Liu

  • Fang Wang

  • July 14, 2026

Share

  • 1

    IgA nephropathy (IgAN) is a prevalent form of primary glomerulonephritis that can lead to renal failure requiring dialysis.

  • 2

    Telitacicept, an APRIL and BAFF inhibitor, has shown potential as a treatment for IgAN patients with eGFR over 30 mL/min/1.73 m².

  • 3

    A 47-year-old male with stage 4 CKD and acute renal failure was treated with telitacicept, resulting in decreased proteinuria and improved eGFR.

  • 4

    After 18 months of treatment, the patient's serum albumin levels increased, and hematuria gradually declined without adverse events.

  • 5

    This case highlights the need for further research on telitacicept's efficacy in patients with advanced chronic kidney disease.

Original Source(s)

Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure

  • by Fang Zeng, Fei Tan, Dehui Liu, Fang Wang

  • July 14, 2026

Related Content

Serum and urinary golgi membrane protein 1 (GOLM1/GP73/G73) for chronic kidney disease staging

Point of Care Ultrasound: Bringing Clinicians Back to the Bedside

FDA Expands Test for Gastric and Esophageal Cancers

According to Agilent Technologies, the expanded indication covers esophageal and gastric tumor types and applies to patients being considered for nivolumab or nivolumab and hyaluronidase-nvhy.